Unlike with many other states, no action on ‘aid in dying' bills in Missouri
Marilyn Teitelbaum was determined to have as much fun as she could before taking medication to end her life.
Some of the first signs Teitelbaum had ALS appeared during a vacation to Mexico in 2022. She and her husband, Steven, had taken their grandsons on a trip to Cancun when they noticed Marilyn's foot was dragging, an early sign of her impending nerve degeneration.
The average patient dies within a few years of diagnosis. What starts as muscle weakness advances to total incapacitation.
'Marilyn didn't want to do that or have the family experience it, so the day that she was diagnosed, she said to the physician that she is not going to go to the end with this,' said Steven Teitelbaum, who has worked as a medical researcher and professor at Washington University in St. Louis for more than 50 years.
Rather than live out the fatal disease, which leads to permanent paralysis, Teitelbaum took another trip, this time to Colorado — one of 10 states, plus Washington, D.C., where physician-assisted dying is legal. Under the laws, physicians can prescribe life-ending medication to terminally ill patients who request it.
Before establishing residency in Colorado, the couple rented an ocean-front house in Hawaii for a week, and the family flew out to join. The grandsons took surfing lessons and played soccer. They took a helicopter tour. They had parties and events where Marilyn gave away her jewelry.
'She was very gracious,' Teitelbaum said. 'There was no weeping or feeling sorry for herself or anything like that. It was: How much can I enjoy my family, and particularly my grandchildren and children?'
In Colorado, where she had family, the couple hosted celebrations. A nephew who plays the trumpet brought his band to play for her.
But by the time she took the lethal medication nine months after her diagnosis, Marilyn Teitelbaum's disease had advanced rapidly. Quickly losing muscle function and no longer able to stand on her own, she chose to take the medication two weeks ahead of schedule.
'It's a gracious way to go, actually. And when Marilyn did die, she could die with grace,' Teitelbaum said. On Jan. 26, 2023, she woke up and had breakfast. About a half dozen of her closest relatives gathered around her. A nephew played the guitar. 'And it was just going to sleep,' her husband said.
Missouri is one of at least 25 states this year where lawmakers are considering legislation related to physician-assisted dying, a practice controversial enough that there's debate over what to call it. Proponents prefer 'medical aid in dying,' while opponents insist 'physician-assisted suicide' is more forthright.
The American Medical Association takes a stance against physician-assisted suicide as 'fundamentally incompatible with the physician's role as healer,' difficult or impossible to control, and posing serious societal risks, the group's website said.
A 2024 Gallup poll found 66% of Americans believe doctors should 'be allowed by law to assist the patient to commit suicide' when a terminally ill patient in severe pain requests it.
New Mexico, the most recent state to legalize physician-assisted suicide, did so in 2021. Delaware's Democratic governor vetoed a bill to legalize assisted dying in 2024, and in 2023, Republican Nevada Gov. Joe Lombardo similarly vetoed a legalization bill.
Lawmakers in 18 states are considering legislation to legalize physician-assisted suicide. As in a number of other states, Missouri's 'Marilyn Teitelbaum Death with Dignity Act' has languished without a committee hearing.
'We were unable to secure a Republican sponsor for it,' said Rep. Ian Mackey, D-St. Louis, who introduced the bill this year and last. 'Until we can do that, it's not going to get any traction.'
Strong political will exists in Illinois, Delaware and New York to move legislation legalizing assisted dying forward, said Elizabeth Armijo, national director of legislative advocacy at Compassion & Choices.
New York lawmakers are taking up the issue again for the 10th consecutive session. Two identical bills are in health committees in their respective chambers.
A 2024 YouGov poll found 64% of New Yorkers support passing the legislation, and another 8% are leaning toward supporting it. The bill is gaining sponsors in the state's House and Senate quickly, with those in favor of the bill vying for Gov. Kathy Hochul's support.
Between the two bills, 90 lawmakers have signed on as sponsors 'and that number is continuing to grow,' said Corinne Carey of Compassion & Choices. 'I am more hopeful than ever that this will be the year the legislature finally passes the bill.'
In the Illinois General Assembly, two bills are progressing, but face opposition from pro-life advocates and medical professionals.
'This can be an emotional issue, and many fallacies circle medical aid in dying,' said Illinois state Sen. Linda Holmes, who co-sponsored one of the measures, said during a Senate executive committee hearing. 'I encourage those with misgivings to read the legislation in full to see its criteria and the safeguards that would protect patients, medical professionals, and relatives.'
Last year in Delaware, outgoing Gov. John Carney vetoed a bill to legalize the practice after it had passed the state's Senate by one vote. A similar measure this year passed the Delaware House and a Senate committee, and now awaits approval from the full Senate.
'So many of these efforts get incredibly close, and then they're disappointing. They're so disappointing for our terminally ill advocates who don't have the luxury of having one more session,' Armijo said. 'They don't have the luxury of waiting for another legislative session and so often they really die waiting.'
Bills introduced in states where the practice is legal would amend aspects of the law including waiting time or who qualifies to prescribe the medication. Opponents say the efforts remove safeguards while proponents argue these improve access.
Two bills — one in New Jersey and another in Washington — would, for qualifying patients, waive the wait period between the patient's first and second required request for the medication.
Bills in Oregon and Vermont would allow certified licensed nurse practitioners and physician assistants, in addition to physicians, to prescribe the medication. A measure in California would remove the Jan. 1, 2031, sunset on the state's law.
In Montana, a 2009 state Supreme Court ruling permitted the practice; a bill to codify its legality died in March. A competing measure that would make it illegal for doctors to prescribe the medications passed the state Senate but was defeated on the House floor April 9.
'This bill reinforces that life is valuable and should be protected,' said the bill's sponsor, Montana state Sen. Carl Glimm, during a March 19 hearing in the House Judiciary Committee.
As a pathologist, death is a common part of Steven Teitelbaum's life. With physician-assisted dying, he said it's crucial that no one making the decision is encouraged by others to do it.
'If that's not dealt with, then the other side has a very compelling argument,' he said.
Assisted-dying laws in the United States follow the basic criteria of the initial Oregon legalization bill. Geoff Sugerman, who helped write Oregon's Death with Dignity Act, echoed Teitelbaum's concern.
'It's something that always has to be driven by the patient. The patient is the one who really has to initiate that conversation,' said Sugerman, who now works as the national policy advisor for Death with Dignity, an advocacy group.
Jessica Rodgers grew up in Oregon, the first state to legalize assisted dying in 1997, when the debate over the issue began making headlines. Oregon doctors who supported the law publicly advocated for it. Rogers was 12 when her mother was given six months to live after being diagnosed with ovarian cancer. Her mother met the qualifications for assisted dying.
With her father working two jobs, Rodgers took care of her mother. She remembers one of the doctors in her mother's oncology practice was an outspoken advocate for the bill that would become Oregon's Death with Dignity Act.
'As her primary caregiver, it changed how I viewed her doctor's appointments, because I felt as though I needed to protect her from her doctor, and I never wanted her to be alone with her doctor,' Rodgers said.
Her mother lived for three and a half years, long enough to hold her first grandchild, Rodgers said.
Now a social worker who specializes in gerontology, Rodgers has spent the last two decades advocating against physician-assisted suicide. Today she works as the coalitions director at Patients Rights Action Fund.
She fears legalizing assisted death creates a lower standard of care for people who are terminally ill.
The American Academy of Hospice and Palliative Medicine, an industry group, takes a neutral stance on assisted dying, but echoes similar concerns over the practice's effect on 'the perceived or actual integrity of the medical profession,' according to its website.
About 22% of Americans – 74 million people – live in jurisdictions where assisted dying is legal. Between 1998 and 2020, just 5,329 people died using physician-assisted death in the United States. That's according to a 2022 study published in the Journal of the American Geriatrics Society .
Each state collects data differently making it difficult to analyze trends, according to the study's author, Elissa Kozlov, an assistant professor at Rutgers University.
Reporters Maya Burney of Belmont University, Aditi Thube of Boston University and Emma Schwichtenberg of the University of Washington contributed to this story.
This story originally appeared in the Columbia Missourian. It can be republished in print or online.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
A new genetic test may be able to predict obesity in early childhood. What to know
More than 2 out of 5 adults in the U.S. are considered obese, according to the Centers for Disease Control and Prevention. But what if there was a way to test children to find out if they're at higher risk for contracting the chronic condition while still having time to change their lifestyle? In a study published July 21 in the journal Nature Medicine, more than 600 scientists from 500 institutions worldwide compiled genetic data from more than 5 million people. Using data collected by The Genetic Investigation of ANthropometric Traits (GIANT) consortium – an international collaboration of human genetics researchers and 23andMe – a genetic measure known as polygenic risk scores (PGS) was developed to help identify children at higher risk of developing obesity in adulthood. Obesity is a serious, common and costly chronic condition characterized by excessive body fat, often defined as a Body Mass Index (BMI) of 30 or greater. The American Medical Association considers it a significant public health concern, as it increases the risk of numerous conditions, including diabetes and heart disease. What does the study say? Researchers developed ancestry-specific and multi-ancestry polygenic risk scores and found they were about twice as effective as the risk assessments doctors currently use. For people with European ancestry, the newly developed risk score accounted for about 17.6% of a person's risk of developing a high BMI in adulthood. About 70% of participants whose genetic data was compiled in the study had predominantly European ancestry, 14.4% had Hispanic ethnicity with typically mixed ancestries, 8.4% had predominantly East Asian ancestry, 4.6% had predominantly African ancestry and 1.5% were of predominantly South Asian origin, according to the research. Ruth Loos, a co-author of the study, is a professor at the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen. In an interview with NBC News, she explained, 'Obesity is not only about genetics, so genetics alone can never accurately predict obesity.' 'For the general obesity that we see all over the world, we need other factors, such as lifestyle, that need to be part of the predictions,' added Loos. Obesity increases the risk of nearly 200 diseases and can cause serious health conditions like asthma, strokes, Type 2 diabetes and some types of cancers. It was a risk factor in 3.7 million deaths in 2021. Globally, obesity in adults has more than doubled since 1990, with adolescent rates quadrupling, the World Health Organization reported. How can communities address obesity? Ensuring access to healthy foods, safe places for physical activity, stigma-free obesity prevention and treatment programs, and evidence-based health care services such as medication and surgery are examples of how to address and prevent obesity, according to the CDC. Director of the CDC's National Center for Chronic Disease Prevention and Health Promotion, Karen Hacker previously told USA TODAY that there is no singular approach to addressing the health concern. 'Obesity is a disease caused by many factors, including eating patterns, physical activity levels, sleep routines, genetics and certain medications. This means that there is no one-size-fits-all approach, Hacker said. 'However, we know the key strategies that work include addressing the underlying social determinants of health, such as access to health care, healthy and affordable food and safe places for physical activity,' Hacker added. This article originally appeared on USA TODAY: A new genetic test may be able to predict obesity in early childhood Solve the daily Crossword
Yahoo
15 hours ago
- Yahoo
China is catching up to the US in brain tech, rivaling firms like Elon Musk's Neuralink
'I want to eat' popped up in Chinese characters on a computer at a public hospital in central Beijing. The words were formed from the thoughts of a 67-year-old woman with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease, who is unable to speak. The demonstration, captured on video in March by Beijing Radio and Television Station, was part of a clinical trial involving five patients implanted with a coin-sized chip called Beinao-1, a wireless so-called brain computer interface (BCI) – a technology led by scientists in the US, but in which experts say China is quickly catching up. Luo Minmin, director of the Chinese Institute for Brain Research (CIBR) and the chief scientist behind the trial, said there was a 'very strong' need for BCI technology, saying they had been 'overwhelmed' by requests from potential patients. 'The patients were saying that this feels so great, like they can gain or regain the control of (their) muscles,' he told CNN in May during a rare interview at his lab, located an hour's drive away from Beijing Xuanwu Hospital, where the trial took place. Luo said the technology was showing 'high accuracy' in decoding signals from the brains of patients and translating the signals into text speech or machine movements. His team is planning to speed up human trials by implanting chips into 50 to 100 more patients over the next year. 'We are hoping that we can move this process faster,' he said. 'If it's proven to be safe and effective … it can be used clinically across the world.' As of May, Beinao-1 says a total of five patients, the same number as Elon Musk's Neuralink, has its implants. Another US company Synchron, whose investors include Jeff Bezos and Bill Gates, has undergone trials with 10 patients, six in the United States and four in Australia. Maximilian Riesenhuber, a professor of neuroscience at Georgetown University who was not involved in the Beinao trials, told CNN that despite starting later than the US, China is making advances. 'China has definitely shown the ability to not just catch up, but also then be competitive, and now actually to start, also to drive the field in some areas,' he said. 'Excitingly, there's a lot of research activities in both countries, because they've realized the potential in BCI.' According to Precedence Research, a market research firm, the market for brain technology was worth about $2.6 billion last year and is expected to rise to $12.4 billion by 2034. But for both China and the US, this technology is about much more than cash. Chinese leader Xi Jinping has long aimed to turn his country into a science and economic powerhouse. In March, he wrote in state-owned media that the tech industry had become the 'forefront' and 'main battlefield' of global competition. His ambitions have sparked concern in the US, resulting in an ongoing tech war, particularly in the semiconductor industry. A different approach CIBR was jointly founded by the Beijing municipal government and several local universities in 2018, about two years after Elon Musk founded Neuralink near San Francisco. In 2023, CIBR incubated a private company named NeuCyber NeuroTech to focus on brain tech products such as Beinao-1. Luo, who is also the startup's chief scientist, gave CNN rare access to the institute in May. For years, he said, the ALS patient, who is in her 60s, was unable to express herself. 'She's awake, she knows what she wants but she could not speak out,' said the scientist, who got his PhD in neuroscience from the University of Pennsylvania and spent nearly a decade in the US. 'Following the implantation, she can now speak simple sentences quite accurately via the system.' All BCI researchers must address the balance between risk and effectiveness. Riensenhuber said most American firms use the more invasive method to place chips inside the dura mater, an outer layer of tissue that covers and protects the brain and spinal cord, in order to capture better signal. But these methods require riskier surgeries. 'It is interesting to see that NeuCyber is apparently able to get enough information even through the dura to allow the decoding of specific words,' he said. The test on the ALS patient, which began in March, marked the Beinao-1 chip's third trial in humans. Those trials made up what the developers described in a press release as 'the world's first batch of semi-invasive implantation of wireless BCI in human brains.' As of May, two more trials have been conducted, for a total of five. Clear ambition Amid rising geopolitical tensions, comparisons between US and Chinese tech breakthroughs are common. Brain computer interface technology first started in the 1970s in the US. Decades later, the Obama Administration launched its 'Brain Initiative' in 2013, investing more than $3 billion to fund over a thousand neuroscience technology projects since, according to the National Institute of Health. Synchron, based in New York, was the first firm to start human trials in July 2021. Three years later, a new BCI system developed at UC Davis Health translated the brain signals of an ALS patient into speech, achieving an accuracy of 97% – the most accurate system of its kind, the university said in a statement. The same year, Musk's company completed its first human trial, enabling the participant to control a computer mouse with a brain implant. China got its start in brain tech only in the 1990s, but it's advancing fast. In 2014, Chinese scientists introduced the idea of a national project on brain tech to match similar efforts in the US and Europe, according to the Ministry of Science and Technology. Two years later, brain tech was mentioned in the country's five-year plan, which outlines China's national priorities and goals. 'Brain science is new in China,' said Lily Lin, a former research assistant at one of China's top neuroscience research units from 2021 to 2023. 'So, it started a bit late, but its speed of development has been faster than other countries. And the country has given a lot of funding to many scientific research units, and this funding is increasing every year.' Last year, the government issued its first ethical guidelines for research in this area. At the local level, municipal governments in Beijing, Shanghai and other major cities have also offered support for brain technology companies from research and clinical trials to commercialization. Riesenhuber and other researchers from Georgetown University published research on China's BCI development in 2024, stating that efforts from Chinese researchers were 'comparable in sophistication' to those in the US and the United Kingdom. 'We found China's non-invasive BCI research to be comparable with that of other scientifically advanced nations and to be working to overcome obstacles to greater fidelity, throughput, and wider use,' according to the issue brief. 'China's invasive BCI research, while historically behind its non-invasive efforts, has picked up the pace and is approaching global standards of sophistication.' Luo, who has worked in both countries, says the US is the 'front-runner' in both invasive and non-invasive brain tech. But, comparing Beinao-1 and Neuralink is like looking at 'apples and oranges,' he added. The two systems differ not only in implant location but also in the type of brain signals recorded, as well as the method of data transmission. The Chinese chip records a wider range of brain areas, with lower precision for each neuron. 'All in all, I don't think these two products are in a competitive or exclusive relationship,' Luo added. 'The jury is still out, and we don't know yet which route will ultimately benefit patients better.' CNN's Joyce Jiang contributed to this report.


Boston Globe
2 days ago
- Boston Globe
An attack on the medical establishment buried in an 1,800-page regulation
Medicare officials have been loath to change it because it has spared them from needing their own staff and budget to make such pricing decisions, along with the unpleasant politics of adjudicating conflicts between competing groups of physicians. But a change buried inside a 1,803-page proposed regulation published last Monday suggests the Trump administration would like to move away from this longstanding system. If finalized, it could begin overturning a process that has entrenched pay advantages for certain kinds of doctors. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up 'We're modernizing Medicare by correcting outdated assumptions in how physician services are valued,' said Chris Klomp, a deputy administrator of the Centers for Medicare and Medicaid Services, in an email. Advertisement Robert F. Kennedy Jr., the secretary of health and human services, has emphasized that medicine should focus more on primary care and prevention, and less on the treatment of advanced diseases. He has also crusaded against 'corporate medicine,' and has specifically criticized the American Medical Association. Stat News reported in November that Kennedy was considering policies to disempower the AMA committee. Advertisement Dr. Bobby Mukkamala, the AMA's president, was highly critical of the proposed change. 'The American Medical Association believes that proposals to exclude or limit the input of expert practicing physicians and health care professionals in the development of Medicare payment policy would ultimately harm patients and represents a radical departure from the time-tested CMS decision-making process,' he said in a statement. The current AMA committee, known as the RUC, uses data gathered in surveys of doctors to set formulas for every kind of medical care. The committee suggests payment rates to Medicare's regulators, who almost always adopt them. The system is effectively zero-sum — any increases for one kind of doctor represents decreases for others. While private insurers are free to develop their own formulas for paying doctors, they tend to follow Medicare's lead, making the committee very influential on what kinds of medical care get the largest (and smallest) financial rewards. The estimates are often outdated. Existing payments are reviewed on average only once every 17 years. A Washington Post investigation in 2013 reported on numerous gastroenterologists who had billed Medicare for more than 24 hours' worth of colonoscopies a day. The reason wasn't fraud. Medicare was still paying the doctors as if each test took 75 minutes to complete, when most doctors were able to complete one in 30 minutes. (The colonoscopy payment has since been adjusted.) Under the new proposal, Medicare would pay 2.5 percent less for every procedure, operation and medical test in 2026, based on data suggesting there have been improvements in 'efficiency' over the years. Payments for treatments based only on time, like a consultation with a family physician or neurologist, would not be cut. Such adjustments would be repeated every three years. Advertisement The proposal also looks to change the kind of data Medicare should consider instead of the relatively small surveys, noting that new sources of health data from hospitals and electronic billing systems could offer more accurate information. The effort to adjust what doctors are paid for their work is just one part of the large rule, which also contains provisions to broaden coverage for telemedicine, pay for more mental health care, and reduce overpayments for a new and expensive type of skin bandage. One other provision, meant to better account for the costs of running a medical practice, also affects the relative pay of different medical specialists. In some cases, those changes would reduce payments to the types of medical specialists whom the efficiency adjustments are meant to benefit. That policy would adjust payments to doctors based on whether they offer services on a hospital campus or in a private practice office, effectively lowering payments in the hospital and boosting those elsewhere. Taken together, the overall proposal would do more than just increase the salaries of primary care doctors. It would also increase the average pay of an allergist next year by 7 percent, and decrease pay for a neurosurgeon by 5 percent, according to estimates published by Medicare. It would lower pay by 6 percent for infectious disease specialists, who tend to earn low salaries and perform few procedures -- and increase average pay for vascular surgeons by 5 percent. Dr. Adam Bruggeman, a spine surgeon in San Antonio who leads the council on advocacy for the American Academy of Orthopaedic Surgeons, said he was sympathetic to arguments that the current system may be paying for some medical procedures inaccurately. But he said the proposal — which would cut payments for all procedures next year — was too crude a solution to that problem. He described the 'efficiency' changes as 'taking an ax to the whole thing.' Advertisement 'We're just fighting an arbitrary number with another arbitrary number, and that doesn't help,' he said. This article originally appeared in